Donor‐Derived T‐Cell Redirection With Epcoritamab Achieving Complete Response After Early Post‐Allo‐HSCT Relapse of DLBCL
This observation suggests that donor-derived T-cell redirection with epcoritamab may enhance antitumor efficacy while maintaining safety in the post-transplant setting, supporting its potential as a salvage therapy for relapsed DLBCL post-allo-HSCT.
Authors
- Nobuhiro Kanemura (ORCID: https://orcid.org/0000-0001-8449-9918)
- Yoshikazu Ikoma (ORCID: https://orcid.org/0009-0008-4780-9137)
- Masahito Shimizu (ORCID: https://orcid.org/0000-0002-1151-2058)
- Hideko Goto
- Nobuhiko Nakamura (ORCID: https://orcid.org/0000-0003-1682-7777)
- Ryoma Shimazu (ORCID: https://orcid.org/0009-0009-3907-3964)
- Yuto Kaneda (ORCID: https://orcid.org/0009-0005-5910-0609)
- Naoki Katsumura
- Daisuke Okamoto (ORCID: https://orcid.org/0000-0002-7381-377X)
- Hiroshi Nakamura (ORCID: https://orcid.org/0000-0001-7699-9840)
- Takuro Matsumoto (ORCID: https://orcid.org/0000-0001-5589-8573)
Institutions
- Gifu Municipal Hospital (JP)
- Gifu University Hospital (JP)
Publication Details
- Journal
- eJHaem
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1002/jha2.70186
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00